Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects

References

• Arlauckas SP, Garris CS, Kohler RH, et al. (2017). In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:eaal3604.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. (2012). The tumor microenvironment at a glance. J Cell Sci 125:5591–6.
   PubMed Web of Science ®Google Scholar
• Bomar L, Senithilnathan A, Ahn C. (2019). Systemic therapies for advanced melanoma. Dermatol Clin 37:409–23.
   PubMed Web of Science ®Google Scholar
• Burugu S, Dancsok AR, Nielsen TO. (2018). Emerging targets in cancer immunotherapy. Semin Cancer Biol 52:39–52.
   PubMed Web of Science ®Google Scholar
• Castañeda-Reyes ED, Perea-Flores MJ, Davila-Ortiz G, et al. (2020). Development, characterization and use of liposomes as amphipathic transporters of bioactive compounds for melanoma treatment and reduction of skin inflammation: a review. Int J Nanomedicine 15:7627–50.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. (2013). Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–91.
   PubMed Web of Science ®Google Scholar
• De Palma M, Lewis CE. (2013). Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23:277–86.
   PubMed Web of Science ®Google Scholar
• Duncan LM. (2009). The classification of cutaneous melanoma. Hematol Oncol Clin North Am 23:501–13, ix.
   PubMed Web of Science ®Google Scholar
• Fang DD, Tang Q, Kong Y, et al. (2019). MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer 7:327.
   PubMed Web of Science ®Google Scholar
• Fan B, Kang L, Chen L, et al. (2017). Systemic siRNA delivery with a dual pH-responsive and tumor-targeted nanovector for inhibiting tumor growth and spontaneous metastasis in orthotopic murine model of breast carcinoma. Theranostics 7:357–76.
   PubMed Web of Science ®Google Scholar
• Fan Q, Ma Q, Bai J, et al. (2020). An implantable blood clot-based immune niche for enhanced cancer vaccination. Sci Adv 6:eabb4639.
   Web of Science ®Google Scholar
• Feng Y, Sun C, Yuan Y, et al. (2016). Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. Int J Pharm 501:342–9.
   PubMed Web of Science ®Google Scholar
• Hagemann T, Lawrence T, McNeish I, et al. (2008). "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261–8.
   PubMed Web of Science ®Google Scholar
• Hou N, Liu N, Han J, et al. (2017). Chlorogenic acid induces reactive oxygen species generation and inhibits the viability of human colon cancer cells. Anticancer Drugs 28:59–65.
   PubMed Web of Science ®Google Scholar
• Huang S, Wang LL, Xue NN, et al. (2019). Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. Theranostics 9:6745–63.
   PubMed Web of Science ®Google Scholar
• Huang S, Zhang Y, Wang L, et al. (2020). Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier. J Control Release 325:10–24.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Chao MP, Majeti R, Weissman IL. (2010). Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31:212–9.
   PubMed Web of Science ®Google Scholar
• Jayant S, Khandare JJ, Wang Y, et al. (2007). Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res 24:2120–30.
   PubMed Web of Science ®Google Scholar
• Ji W, Li L, Zhou S, et al. (2020). Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response. J Drug Target 28:982–90.
   PubMed Web of Science ®Google Scholar
• Li HR, Habasi M, Xie LZ, Aisa HA. (2014). Effect of chlorogenic acid on melanogenesis of B16 melanoma cells. Molecules 19:12940–8.
   PubMed Web of Science ®Google Scholar
• Lu D, Ni Z, Liu X, et al. (2019). Beyond T cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J Immunol Res 2019:1919082.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561–84.
   PubMed Web of Science ®Google Scholar
• Marshall HT, Djamgoz MBA. (2018). Immuno-oncology: emerging targets and combination therapies. Front Oncol 8:315.
   PubMed Web of Science ®Google Scholar
• Morrison C. (2016). Immuno-oncologists eye up macrophage targets. Nat Rev Drug Discov 15:373–4.
   PubMed Web of Science ®Google Scholar
• Nath D, Hartnell A, Happerfield L, et al. (1999). Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98:213–9.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–64.
   PubMed Web of Science ®Google Scholar
• Pathria P, Louis TL, Varner JA. (2019). Targeting tumor-associated macrophages in cancer. Trends Immunol 40:310–27.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Ribas A, Robert C, et al. (2020). Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials. JAMA Oncol 6:1256–64.
   PubMed Web of Science ®Google Scholar
• Qian Y, Qiao S, Dai Y, et al. (2017). Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano 11:9536–49.
   PubMed Web of Science ®Google Scholar
• Qiu Q, Li C, Song Y, et al. (2019). Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta Biomater 92:184–95.
   PubMed Web of Science ®Google Scholar
• Queirolo P, Boutros A, Tanda E, et al. (2019). Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol 59:290–7.
   PubMed Web of Science ®Google Scholar
• Schauer R. (2009). Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 19:507–14.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. (2015). The future of immune checkpoint therapy. Science 348:56–61.
   PubMed Web of Science ®Google Scholar
• She Z, Zhang T, Wang X, et al. (2014). The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate. Biomaterials 35:5216–25.
   PubMed Web of Science ®Google Scholar
• Tang X, Sui D, Liu M, et al. (2020). Targeted delivery of zoledronic acid through the sialic acid – Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages – a promising cancer immunotherapy. Int J Pharm 590:119929.
   PubMedGoogle Scholar
• Taube JM, Klein A, Brahmer JR, et al. (2014). Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–74.
   PubMed Web of Science ®Google Scholar
• Tomita M, Suzuki M, Kono Y, et al. (2020). Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res 10:24.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–71.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Wang Y, Tiruthani K. (2019). Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. Nanomedicine 21:102034.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Izawa Y, Onodera D, Tagami M. (2018). Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells. Mol Cell Biochem 441:9–19.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu N, Hou N, et al. (2017). Chlorogenic acid inhibits hepatocellular carcinoma in vitro and in vivo. J Nutr Biochem 46:68–73.
   PubMed Web of Science ®Google Scholar
• Yang Q, Guo N, Zhou Y, et al. (2020). The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B 10:2156–70.
   PubMed Web of Science ®Google Scholar
• Zeng A, Liang X, Zhu S, et al. (2021). Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF‑κB signaling pathway. Oncol Rep 45:717–27.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xie J, Arai S, et al. (2016). The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7:73068–79.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Y, Ye J, et al. (2020). Construction of chlorogenic acid-containing liposomes with prolonged antitumor immunity based on T cell regulation. Sci China Life Sci 64:1097–1115.
   PubMed Web of Science ®Google Scholar
• Zhang F, Yin G, Han X, et al. (2019). Chlorogenic acid inhibits osteosarcoma carcinogenesis via suppressing the STAT3/Snail pathway. J Cell Biochem 120:10342–50.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhang T, Peng B, et al. (2017). Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Int J Pharm 523:203–16.
   PubMed Web of Science ®Google Scholar
• Zhu S, Luo Z, Li X, et al. (2021). Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. J Cancer 12:54–64.
   PubMed Web of Science ®Google Scholar